Lumos Diagnostics Holdings Limited (ASX:LDX)

Australia flag Australia · Delayed Price · Currency is AUD
0.1500
-0.0100 (-6.25%)
Apr 28, 2026, 4:10 PM AEST
Market Cap147.63M +839.2%
Revenue (ttm)18.31M -16.7%
Net Income-13.88M
EPS-0.02
Shares Out922.70M
PE Ration/a
Forward PE0.16
Dividendn/a
Ex-Dividend Daten/a
Volume6,716,343
Average Volume6,672,374
Open0.1650
Previous Close0.1600
Day's Range0.1500 - 0.1700
52-Week Range0.0240 - 0.3300
Beta0.81
RSI29.19
Earnings DateApr 20, 2026

About ASX:LDX

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platfor... [Read more]

Sector Healthcare
Founded 2018
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol LDX
Full Company Profile

Financial Performance

In fiscal year 2025, ASX:LDX's revenue was $12.40 million, an increase of 11.40% compared to the previous year's $11.13 million. Losses were -$7.18 million, -16.40% less than in 2024.

Financial numbers in USD Financial Statements